BridgeMD
New treatment option for Defective Composite Restorations
Official title Bone Reconstruction With Autologous Bone Marrow Mesenchymal Stem Cells in Vitro to Repair Long Tubular Bone Defects
ClinicalTrials.gov ID: NCT07066228
What this study is testing
- What it's testing
- Commercial decalcified bone scaffolds were combined with autologous bone marrow mesenchymal stem cells to form tissue engineered bone in vitro to explore the effect of this tissue engineered bone in the clinical repair of long tubular bone defects in limbs.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55
You may be able to join if
- Age: 18-55 years old, gender unrestricted;
- Defective nonunion with bone loss exceeding 30% of the bone cross-section and a length of 2-3 cm;
- Solitary bone cysts involving more than 50% of the bone cross-section.
You likely can't join if
- Combined with local tumors, tuberculosis, infections or other bone-healing affecting lesions;
- Systemic diseases affecting bone healing such as osteofibrous dysplasia, osteogenesis imperfecta, bone dystrophic diseases, and metabolic bone...
- Moderate-to-severe osteoporosis (BMD: T-score \< -2.5);
- Severe systemic conditions including systemic malnutrition, systemic infectious diseases, severe cardiopulmonary diseases, coagulation disorders, and...
- Complicated with severe brain trauma;
- Heavy smoking, drug abuse, alcoholism, or other harmful addictions;
See the full eligibility criteria
- Age: 18-55 years old, gender unrestricted;
- Defective nonunion with bone loss exceeding 30% of the bone cross-section and a length of 2-3 cm;
- Solitary bone cysts involving more than 50% of the bone cross-section.
- Combined with local tumors, tuberculosis, infections or other bone-healing affecting lesions;
- Systemic diseases affecting bone healing such as osteofibrous dysplasia, osteogenesis imperfecta, bone dystrophic diseases, and metabolic bone disorders;
- Moderate-to-severe osteoporosis (BMD: T-score \< -2.5);
- Severe systemic conditions including systemic malnutrition, systemic infectious diseases, severe cardiopulmonary diseases, coagulation disorders, and major organ failure;
- Complicated with severe brain trauma;
- Heavy smoking, drug abuse, alcoholism, or other harmful addictions;
- Psychiatric disorders or patients with menopausal symptoms;
- Concurrent participation in other studies or recent completion (within 4 weeks) of other clinical trials;
- Pregnancy, lactation, or planned pregnancy within one year after initial enrollment;
- Psychological conditions impairing treatment compliance;
- Congenital malformations of vital organs or other systems;
- Nonunion caused by malignant tumor resection;
- Refusal to accept tissue-engineered bone repair protocol.
The study team makes the final eligibility decision.
Where it's taking place
- Xinxiang, Henan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Xinxiang, Henan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.